Adenosine A2A receptor

iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations

Retrieved on: 
Monday, June 14, 2021
Life sciences, Biotechnology, Health sciences, Adenosine A2A receptor, Biopharmaceutical, Adenosine

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients.

Key Points: 
  • iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients.
  • The Company is also advancing inupadenant, a first insurmountable adenosine A2A receptor antagonist in clinical development tailored to overcome cancer immunosuppression.
  • iTeos is conducting an open-label multi-arm Phase 1/2a clinical trial of inupadenant in adult cancer patients with advanced solid tumors.
  • Any of the foregoing risks could materially and adversely affect the Companys business, results of operations and the trading price ofiTeos common stock.

Impact of Baseline Dyskinesia on Safety and Efficacy of NOURIANZ® (istradefylline) in Patients with Parkinson's Disease Presented During "Virtual" European Academy of Neurology Meeting

Retrieved on: 
Tuesday, May 26, 2020
Organ systems, Organic compounds, Neurological disorders, Parkinson's disease, Nervous system, Istradefylline, Xanthines, Adenosine A2A receptor, Dyskinesia, Amines, Levodopa-induced dyskinesia, Tardive dyskinesia

These findings were presented during the 6th Congress of the European Academy of Neurology (EAN).

Key Points: 
  • These findings were presented during the 6th Congress of the European Academy of Neurology (EAN).
  • "The results being presented at EAN suggest that dyskinesia is observed more often in patients with baseline dyskinesia before istradefylline was added to the treatment regimen and that the overall efficacy of istradefylline was not affected by patients' baseline status.
  • While these data provide further information, physicians should continue to monitor patients for dyskinesia or exacerbation of existing dyskinesia during NOURIANZ treatment.
  • Impact of Baseline Dyskinesia on the Safety and Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, in Patients with Parkinson's Disease: a Pooled Analysis of 8 Clinical Studies.

iTeos Therapeutics to Present Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020

Retrieved on: 
Monday, April 20, 2020
Branches of biology, Adenosine receptors, Medical specialties, Adenosine A2A receptor, TIGIT, Adenosine, Medicine

Gosselies, Belgium and Cambridge, MA April 20, 2020. iTeos Therapeutics, a privately-held biotechnology company developing novel cancer immunotherapies, announces today that it will present initial data on the first-in-human study of its highly innovative and differentiated A2A receptor antagonist, EOS-850 in a virtual poster presentation at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting 2020, taking place April 27-28th.

Key Points: 
  • Gosselies, Belgium and Cambridge, MA April 20, 2020. iTeos Therapeutics, a privately-held biotechnology company developing novel cancer immunotherapies, announces today that it will present initial data on the first-in-human study of its highly innovative and differentiated A2A receptor antagonist, EOS-850 in a virtual poster presentation at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting 2020, taking place April 27-28th.
  • The Companys lead program, EOS-850, is a best-in-class adenosine A2A receptor antagonist currently in a Phase 1/2 study.
  • Its second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS-448), entered the clinic in February 2020.
  • iTeos Therapeutics is headquartered in Cambridge, MA with a world-class research center in Gosselies, Belgium.

iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers

Retrieved on: 
Thursday, February 27, 2020
Medical specialties, Branches of biology, Medicine, Adenosine A2A receptor, Cancer immunotherapy, Adenosine, TIGIT, Oncology

The importance of TIGIT as a target for next-generation immunotherapy is becoming increasingly apparent in our field and, alongside our best-in-class adenosine A2A receptor antagonist EOS-850, iTeos now has two highly innovative immunotherapy programs in clinical development for patients suffering with advanced cancers.

Key Points: 
  • The importance of TIGIT as a target for next-generation immunotherapy is becoming increasingly apparent in our field and, alongside our best-in-class adenosine A2A receptor antagonist EOS-850, iTeos now has two highly innovative immunotherapy programs in clinical development for patients suffering with advanced cancers.
  • Joanne Lager, M.D., Chief Medical Officer of iTeos, added, ADCC-enabled antagonist anti-TIGIT programs are emerging as promising new immuno-oncology therapies.
  • This Phase 1/2 study of EOS-448 is an open-label, dose-escalation study to assess the safety, pharmacokinetic, pharmacodynamic and preliminary clinical activity of EOS-448 in participants with advanced cancers.
  • The Companys lead program, EOS-850, is a best-in-class adenosine A2A receptor antagonist currently in a Phase 1/2 study.

iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers

Retrieved on: 
Thursday, February 27, 2020
Medical specialties, Branches of biology, Medicine, Adenosine A2A receptor, Cancer immunotherapy, Adenosine, TIGIT, Oncology

The importance of TIGIT as a target for next-generation immunotherapy is becoming increasingly apparent in our field and, alongside our best-in-class adenosine A2A receptor antagonist EOS-850, iTeos now has two highly innovative immunotherapy programs in clinical development for patients suffering with advanced cancers.

Key Points: 
  • The importance of TIGIT as a target for next-generation immunotherapy is becoming increasingly apparent in our field and, alongside our best-in-class adenosine A2A receptor antagonist EOS-850, iTeos now has two highly innovative immunotherapy programs in clinical development for patients suffering with advanced cancers.
  • Joanne Lager, M.D., Chief Medical Officer of iTeos, added, ADCC-enabled antagonist anti-TIGIT programs are emerging as promising new immuno-oncology therapies.
  • This Phase 1/2 study of EOS-448 is an open-label, dose-escalation study to assess the safety, pharmacokinetic, pharmacodynamic and preliminary clinical activity of EOS-448 in participants with advanced cancers.
  • The Companys lead program, EOS-850, is a best-in-class adenosine A2A receptor antagonist currently in a Phase 1/2 study.

iTeos Therapeutics to Present at Cowen 40th Annual Health Care Conference

Retrieved on: 
Monday, February 24, 2020
TIGIT, Adenosine A2A receptor

Cambridge, MA and Gosselies, Belgium February 24, 2020 iTeos Therapeutics SA, a privately-held biotechnology company developing innovative cancer immunotherapies, today announced that Michel Detheux, Ph.D., president and chief executive officer, will present at the upcoming Cowen 40th Annual Health Care Conference on Monday, March 2, 2020 at 3:30 p.m.

Key Points: 
  • Cambridge, MA and Gosselies, Belgium February 24, 2020 iTeos Therapeutics SA, a privately-held biotechnology company developing innovative cancer immunotherapies, today announced that Michel Detheux, Ph.D., president and chief executive officer, will present at the upcoming Cowen 40th Annual Health Care Conference on Monday, March 2, 2020 at 3:30 p.m.
  • iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of people living with cancer by designing and developing next generation immunotherapies targeting two key resistance pathways to checkpoint therapy: the adenosine pathway and regulatory T cells (Tregs).
  • The Companys lead program, EOS-850, is an adenosine A2A receptor antagonist currently in a Phase 1/2 study.
  • A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS-448), is expected to enter the clinic in first quarter of 2020. iTeos Therapeutics is headquartered in Cambridge, MA with world-class research center in Gosselies, Belgium.

iTeos Therapeutics Announces Collaboration with Merck Investigating the Combination of its A2A Antagonist with KEYTRUDA®

Retrieved on: 
Thursday, December 12, 2019
Branches of biology, Biochemistry, Adenosine receptors, Drugs, Bayer AG, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Adenosine A2A receptor, Receptor antagonist, ATL-444

Joanne Jenkins Lager, M.D, Chief Medical Officer of iTeos Therapeutics, commented: We believe that our differentiated, selective A2A receptor antagonist will be complementary to a range of immuno-oncology approaches and we are excited to initiate our first combination study of EOS100850 with KEYTRUDA.

Key Points: 
  • Joanne Jenkins Lager, M.D, Chief Medical Officer of iTeos Therapeutics, commented: We believe that our differentiated, selective A2A receptor antagonist will be complementary to a range of immuno-oncology approaches and we are excited to initiate our first combination study of EOS100850 with KEYTRUDA.
  • Unlike other A2A antagonists, EOS100850 was purposely designed to have very high potency in the tumor micro-environment and unique selectivity for the A2A receptor.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA.
  • The Companys lead program, EOS100850, is a selective adenosine A2A receptor antagonist currently in a Phase 1/1b study.

iTeos Therapeutics Announces Collaboration with Merck Investigating the Combination of its A2A Antagonist with KEYTRUDA®

Retrieved on: 
Thursday, December 12, 2019
Branches of biology, Biochemistry, Adenosine receptors, Drugs, Bayer AG, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Adenosine A2A receptor, Receptor antagonist, ATL-444

Joanne Jenkins Lager, M.D, Chief Medical Officer of iTeos Therapeutics, commented: We believe that our differentiated, selective A2A receptor antagonist will be complementary to a range of immuno-oncology approaches and we are excited to initiate our first combination study of EOS100850 with KEYTRUDA.

Key Points: 
  • Joanne Jenkins Lager, M.D, Chief Medical Officer of iTeos Therapeutics, commented: We believe that our differentiated, selective A2A receptor antagonist will be complementary to a range of immuno-oncology approaches and we are excited to initiate our first combination study of EOS100850 with KEYTRUDA.
  • Unlike other A2A antagonists, EOS100850 was purposely designed to have very high potency in the tumor micro-environment and unique selectivity for the A2A receptor.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA.
  • The Companys lead program, EOS100850, is a selective adenosine A2A receptor antagonist currently in a Phase 1/1b study.

XOMA Acquires Royalty Interest Position in Six Clinical-Stage Assets

Retrieved on: 
Thursday, September 26, 2019
Signal transduction, Cell signaling, Branches of biology, Adenosine receptors, Adenosine A2A receptor, Novartis, Adenosine, Gevokizumab

EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L.

Key Points: 
  • EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L.
  • The six royalty interest assets are:
    NIR178, a potent oral adenosine A2A receptor antagonist being developed by Novartis as a novel checkpoint inhibitor for the treatment of solid tumors.
  • Under the terms of the agreement, XOMA will receive low single-digit royalties on future sales of these six adenosine receptor assets.
  • Any references to assets in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.

Kyowa Kirin Announces FDA Acceptance of Istradefylline (KW-6002) New Drug Application Resubmission in the US

Retrieved on: 
Thursday, April 4, 2019
Seniors, Health, Biotechnology, Pharmaceutical, FDA, Consumer, Health, Food and Drug Administration, Pharmaceuticals policy, Adenosine receptors, Istradefylline, Xanthines, Prescription Drug User Fee Act, Adenosine A2A receptor, Articles

The target Prescription Drug User Fee Act (PDUFA) action date for a decision by the FDA is in August 27, 2019.

Key Points: 
  • The target Prescription Drug User Fee Act (PDUFA) action date for a decision by the FDA is in August 27, 2019.
  • "We are excited by the possibility of bringing a new medicine to people living with Parkinson's Disease and look forward to working closely with FDA during the review process."
  • Istradefylline, is an A2A receptor antagonist, and if approved by FDA, may provide a novel non-dopaminergic pharmacologic approach to treating OFF episodes for people living with PD.
  • Kyowa Hakko Kirin Co., Ltd. is a research-based life sciences company, with special strengths in biotechnologies.